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Abstract Cardiac surgery with cardiopulmonary bypass
(CPB) frequently leads to systemic inflammatory response
syndrome (SIRS) with concomitant organ malfunction.
Infused particles may exacerbate inflammatory syndromes
since they activate the coagulation cascade and alter in-
flammatory response or microvascular perfusion. In a
randomized, controlled, prospective trial, we have previ-
ously shown that particle-retentive in-line filtration pre-
vented major complications in critically ill children. Now,
we investigated the effect of in-line filtration on major
complications in the subgroup of cardiac patients. Children
admitted to tertiary pediatric intensive care unit were ran-
domized to either control or filter group obtaining in-line
filtration throughout complete infusion therapy. Risk dif-
ferences and 95 % confidence intervals (CI) of several
complications such as SIRS, sepsis, mortality, various or-
gan failure and dysfunction were compared between both
groups using the Wald method. 305 children (n = 150
control, n = 155 filter group) with cardiac diseases were
finally analyzed. The majority was admitted after cardiac
surgery with CPB. Risk of SIRS (-11.3 %; 95 % CI -21.8
to -0.5 %), renal (-10.0 %; 95 % CI -17.0 to -3.0 %)
and hematologic (-8.1 %; 95 % CI -14.2 to -0.2 %)
dysfunction were significantly decreased within the filter
group. No risk differences were demonstrated for occur-
rence of sepsis, any other organ failure or dysfunctions
between both groups. Infused particles might aggravate a
systemic hypercoagulability and inflammation with subse-
quent organ malfunction in pediatric cardiac intensive care
patients. Particle-retentive in-line filtration might be ef-
fective in preventing SIRS and maintaining renal and he-
matologic function. In-line filtration offers a novel
therapeutic option to decrease morbidity in cardiac inten-
sive care.
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Introduction
Cardiac surgery with cardiopulmonary bypass (CPB) is
associated with the development of systemic inflammatory
response syndrome (SIRS) [6, 10]. Additionally to the in-
flammatory response due to surgical trauma, several in-
flammatory processes are triggered by the CPB.
Hypothermia, contact of blood with foreign surfaces of the
CPB circuit or ischemia–reperfusion injury due to aortic
cross-clamping and endotoxins generated by splanchnic
hypoperfusion all stimulate multiple inflammatory cas-
cades with humoral and cellular reactions [10]. SIRS often
leads to organ dysfunction or failure [9, 31], increased
mortality and prolonged stay on intensive care unit (ICU)
[27, 31]. Numerous strategies have been developed to
minimize the inflammatory response to CPB such as cor-
ticosteroids, leukocyte depletion, hemofiltration, miniatur-
ized CPB circuits, off-pump surgery and alterations of the
coagulation/anticoagulation management [6, 10]. So far, all
current strategies focused on modification of pre- and in-
traoperative factors. However, the inflammatory processes
may be maintained or even intensified by further treatment
on ICU. So far, no preventive strategy has been established
for ICU management.
Particles arising from infusion therapy on ICU may
aggravate the inflammatory response. Particles have been
shown to generate thrombosis [34], impair microcirculation
[29] and modulate immune response [19]. Sources of par-
ticles include components of infusion systems, incomplete
reconstitution of solutions or drug incompatibility reactions
[19, 30]. Up to one million particles may be infused per
patient per day [19, 20]. In-line filters incorporated into
infusion lines retain particles and thereby nearly entirely
prevent their infusion [19, 29]. In a prospective, random-
ized, controlled trial (ClinicalTrials.gov number;
NCT00209768) including 807 critically ill children, we
have previously demonstrated that in-line filtration reduced
the composite endpoint of severe complications including
sepsis, SIRS and organ failure [7, 20]. Additionally, SIRS
and several organ dysfunctions were reduced as single in-
cidence [7, 20]. Moreover, length of stay (LOS) on pedi-
atric intensive care unit (PICU) and duration of mechanical
ventilation (MV) were also significantly shortened [20].
In the previous study population, we now analyzed the
effect of in-line filtration on major complications in the
subgroup of cardiac patients (n = 305), which has not been
described in detail before. Risk differences of several
complications such as SIRS, sepsis, mortality, various or-
gan failure and dysfunction were compared between both




This was an ancillary study to a single-center, prospective,
randomized, controlled trial regarding in-line filtration
which was conducted between February 2005 and Septem-
ber 2008 on an interdisciplinary PICU of a German univer-
sity hospital (ClinicalTrials.gov number; NCT00209768).
The current investigation focused on the subgroup of chil-
dren with cardiac disease, which have not been investigated
in detail before. Due to safety reasons, use of in-line filters
could not be blinded. The local Ethical committee approved
the research protocol. Upon admission, written informed
consent was obtained for each child from its legal guardians.
Patient Enrollment and Randomization
For the complete study group, patient enrollment and
randomization have been described previously [7, 20].
Patients below 18 years of age admitted to PICU were
assessed for eligibility. Exclusion criteria comprised ex-
pected death within 48 h of admission, recruitment for
other trials, absence of intravenous infusion therapy and
absent parental informed consent. According to a com-
puter-generated simple unrestricted randomization list,
patients were allocated to either control or filter group.
Discharge from PICU within 6 h and discontinuation of
intervention were predefined as exclusion criteria. For the
complete study group, 807 patients (n = 406 control,
n = 401 filter group) were included in the final analysis [7,
20]. Of these patients, 305 children (n = 150 control,
n = 155 filter group) suffered from cardiac diseases.
In-line Filtration
First, a standardized infusion therapy was implemented for
all patients before starting the study [7, 20]. Drug incom-
patibilities were avoided using a computer-based program
(KiK 3.0; oData, Rastede, Germany) [30]. Solutions and
medications were produced according to manufacturer’s
guidelines. In order to guarantee chemical stability and
aseptic standards, a centralized intravenous additive service
provided parenteral nutrition and specific drugs (special
antibiotics, antiviral drugs, antimycotics and chemother-
apy). Administration sets for lipid-containing admixtures
were replaced every 24 h, others every 72 h as recom-
mended by the Robert Koch Institute [23]. To assure an
appropriate and careful handling of in-line filters, all nurses
and physicians received an intensive training.
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Visible in-line filters were obligate for safe drug appli-
cation and surveillance of imminent blockage. Within the
filter group, in-line filters were placed in each lumen of
central and peripheral venous catheters throughout com-
plete infusion therapy [7, 20]. All medications and solu-
tions apart from blood, plasma proteins or fresh frozen
plasma were applied via an in-line filter. Aqueous solutions
were administered via 0.2-lm-pore-size positively charged
filters (ELD96LLCE/NOE96E; Pall, Dreieich, Germany)
and lipid-containing admixtures via 1.2-lm-pore-size fil-
ters (Intrapur Lipid/Intrapur Neonat Lipid; B Braun, Mel-
sungen, Germany). In-line filters were routinely exchanged
after 24 (Intrapur Lipid/Intrapur Neonat Lipid) or 72 h
(ELD96LLCE/NOE96E), or after blockage.
Data Collection
On admission, demographic and clinical data including Risk
Adjustment in Congenital Heart Surgery 1 (RACHS-1) [22]
were recorded in a database. Patients with combined surgical
procedures were assigned to the risk category of the most
complex procedure [22]. Clinical data were documented at
least every hour. Laboratory tests were routinely conducted
on admission and when clinically indicated. In case criteria
for endpoints were fulfilled, this was recorded in the data-
base, which was thoroughly reviewed for consistency. Any
complication prior to PICU stay or present on admission was
not considered. Finally, investigators blinded for random-
ization checked database entries.
Endpoints
Endpoints for the complete study group have been pub-
lished elsewhere [7, 20]. In this investigation, occurrence
of the following major events was analyzed in the subgroup
with cardiac diseases: SIRS, sepsis, mortality, organ failure
(circulation, lung, liver and kidney) or organ dysfunction
(cardiovascular, respiratory, neurologic, hematologic, renal
and hepatic). All complications were defined according to
accepted pediatric consensus recommendations [3, 5, 16,
17, 32]. SIRS, sepsis and organ dysfunction (Electronic
Supplementary Material) were defined according to the
International pediatric sepsis consensus conference
(IPSCC) 2005 [16, 17] and acute respiratory distress syn-
drome (ARDS) analogous to the American-European
Consensus Conference [5]. The Pediatric Acute Liver
Failure Study group determined criteria for acute liver
failure [32]. Circulatory failure was considered as necessity
for any vasoactive or inotropic drug (epinephrine, nore-
pinephrine, dobutamine and dopamine) to maintain blood
pressure above the fifth age-specific percentile [16].
Definition of acute renal failure was based on the Pediatric-
modified Risk, Injury, Failure, Loss, End-stage kidney
disease (pRIFLE) criteria [3]. Finally, mortality rates, LOS
on PICU and duration of MV were assessed for both groups
[7, 20].
Statistical Analysis
Statistical analysis has been described previously [20].
Briefly, due to low mortality rates on PICU, a decrease in
the overall complication rate of major events such as SIRS,
sepsis, thrombosis and several organ failures was defined
as primary endpoint for the complete study group. There-
fore, the initial study was designed on an intention-to-treat
basis to determine a reduction from 40 to 30 % in the
complication rate of major events for the filter group as the
primary endpoint [20]. Size and power of the trial were not
calculated for recognition of a single reduction in a com-
plication for a subgroup.
In this subgroup analysis, demographic data were
compared between control and filter groups using t test for
equality of means. All tests were two-sided. P\ 0.05 was
considered to indicate statistical significance. Data for
duration of MV and LOS on PICU are stated as median and
range, all other data as mean ± SD (95 % CI). The log-
rank test was applied to compare duration of MV and LOS
on PICU. For each endpoint, the risk and its differences
between the both groups including the 95 % confidence
interval (CI) were calculated by the Wald method. If the
95 % CI laid on either side below zero, a statistically
significant difference between both groups was considered.
To exclude any potential influence of differences in base-
line characteristics between both groups, we performed a
multivariable analysis with an adjustment for demographic
parameters. For the multivariable analysis, we used gen-
eralized linear models for estimating risk differences of the
association between filter group and selected outcomes. We
did not find any influence on outcome parameters of po-
tential differences in baseline characteristics. The results
for the adjusted risk differences are presented in Table 2,
and the data for the crude risk differences are additionally
presented in the Electronic Supplementary Material. Sta-
tistical analysis was performed using Predictive Analysis
Software for Windows (SPSS/PASW), version 18.
Results
Subjects
305 children, assigned to either control (n = 150) or filter
group (n = 155), were included in the final analysis
(Table 1). Almost four out of five were admitted after
cardiac surgery (n = 118 control, n = 120 filter group).
Most of them received surgery of congenital heart disease
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(CHD) with cardiopulmonary bypass (n = 102 control,
n = 101 filter group) (Table 1). There were no significant
differences between both groups regarding baseline de-
mographic characteristics, RACHS-1, lowest temperature
during CPB, aortic cross-clamping or cardiopulmonary
bypass times (Table 1).
SIRS, Sepsis, Mortality and Organ Failure
The risk difference of SIRS between the control [36.0 %
(n = 54)] and filter group [25.2 % (n = 39)] was sig-
nificantly different [risk difference = -11.3 % (95 % CI
-21.8 to -0.5 %), (Table 2; Fig. 1, upper panel)]. Though
Table 1 Baseline characteristics of patients
Characteristics Control group (n = 150) Filter group (n = 155) P value
Age (years) 3.1 ± 4.6 3.7 ± 5.5 0.29
Weight (kg) 13.1 ± 14.9 15.5 ± 18.8 0.21
Sex (no.)




Yes 118 120 0.58
CHD with CPB 102 101
Cardiac surgery
Preoperative cyanotic CHD (postoperative persistent)
Yes 48 (10) 45 (11)









6 4 4 0.40
Total-no. 115 119
CPB time (min) 118.4 ± 62.2 113.9 ± 52.3 0.54
Nadir blood temperature (C) during CPB 23.6 ± 5.4 24.0 ± 4.8 0.60
Aortic XCT (min) 47.9 ± 27.9 44.8 ± 26.7 0.43
Total-no. 95 95
Noncardiac surgery
Arrhythmia/conductive disorder 5 6
Cardiomyopathy/myocarditis 6 4
Cyanotic CHD 7 9
Acyanotic CHD
Left-to-right shunt lesion 1 3
Obstructive lesion 6 6
Pulmonary arterial hypertension 4 4
Others 3 3
Total-no. 32 35 0.95
Table shows allocation of patients to control and filter groups according to demographic characteristics, cardiac surgery and noncardiac surgery
entities. None of the differences between the two groups were significant. Data are reported as mean ± SD, or as number (no.) of patients when
indicated
RACHS-1 Risk Adjustment in Congenital Heart Surgery 1, CHD congenital heart disease, CPB cardiopulmonary bypass, Aortic XCT aortic cross-
clamping time
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the incidence of any other complication was decreased in
the filter group, no statistically significant risk differences
could be demonstrated for sepsis, mortality, circulatory
failure, ARDS, acute liver and acute renal failure (Table 2;
Fig. 1, upper panel).
Organ Dysfunction
Patients receiving in-line filtration developed significantly
less renal dysfunction [10.3 % (n = 16) vs. 19.3 %
(n = 29); risk difference = -10.0 %; 95 % CI -17.0 to
-3.0 %; filter vs. control group] (Table 2; Fig. 1, lower
panel) and hematologic dysfunction [5.8 % (n = 9) vs.
12.7 % (n = 19); risk difference = -8.1 %; 95 % CI
-14.2 to -0.2 %; filter vs. control group]. No relevant risk
differences were demonstrated for respiratory, cardiovas-
cular, hepatic and neurologic dysfunction between both
groups (Table 2; Fig. 1, lower panel).
Duration of MV and LOS on PICU
Though not statistically significant, LOS on PICU was
reduced by almost 1 day in the filter group [5.86 days
(95 % CI 4.91 - 6.82) vs. 4.95 days (3.63 - 6.27);
control vs. filter group; P = 0.109], (Table 3). Duration
of MV was approximately 15 h shorter within the filter
group [33.0 h (95 % CI 12.7 - 53.3 h) vs. 18.3 h (4.6 -
31.9 h)], but this difference did not reach statistical sig-
nificance as well.
Discussion
Recently, we conducted a prospective, randomized, con-
trolled trial to evaluate the effect of in-line filtration on
major complications in critically ill children [7, 20]. The
current investigation focused on the subgroup of children
with cardiac diseases in the previously published study
population [7, 20]. This subgroup of cardiac patients has
not been investigated in detail before. In addition to our
previous data [7, 20], we further characterized underlying
cardiac diagnoses, the procedural risk for cardiac surgery
and intraoperative data. Until now, no study has ever in-
vestigated the effect of in-line filtration retaining particles
arising from infusion solutions during stay on cardiac
PICU.
Since use of a contingency table or calculation of a
P value is statistically inappropriate in a subgroup analysis,
we computed risk differences and its 95 % confidence in-
terval (CI) for each endpoint. A statistically significant
difference between control and filter group was assumed, if
the 95 % CI of the risk differences did not contain zero.







Risk difference (%) 95 % CI
SIRS, sepsis, organ failure and mortality
SIRS 54 39 -11.3 -21.8 to (-0.5)*
Sepsis 10 8 -2.0 -6.5 to 2.5
Circulatory failure 35 32 -2.5 -11.8 to 6.7
ARDS 14 7 -3.5 -9.0 to 1.9
Acute renal failure 10 8 -1.6 -7.0 to 3.9
Acute liver failure 6 2 -2.3 -5.3 to 0.6
Mortality 15 7 -5.8 -11.5 to 0.1
Organ dysfunction
Cardiovascular dysfunction 31 28 -2.3 -11.0 to 6.3
Hematologic dysfunction 19 9 -8.1 -14.2 to (-0.2)*
Hepatic dysfunction 10 6 -2.8 -7.8 to 2.2
Neurologic dysfunction 1 1 0.0 -2.0 to 2.0
Renal dysfunction 29 16 -10.0 -17.0 to (-3.0)*
Respiratory dysfunction 27 19 -5.6 -13.6 to 2.4
Table shows incidence of different complications in control and filter groups, risk differences and corresponding 95 % confidence interval (CI)
according to Wald method
Calculation of a P value was statistically inappropriate in a subgroup analysis. Therefore, risk differences in incidence rates and their corre-
sponding 95 % CI were determined. A 95 % CI on either side below zero indicated a statistically significant difference between both groups (*).
SIRS, renal and hematologic dysfunction were significantly reduced in the filter group
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In the light of this methodological approach, our main
findings suggest that in-line filtration is highly effective in
preventing the occurrence of SIRS in cardiac intensive care
patients. Moreover, in-line filtration seemed to preserve
hematologic and renal organ function. Length of stay on
ICU and the duration of MV as well as all other
complications were observed to be decreased in the filter
group, albeit not reaching the level of significance as de-
fined above.
For the evaluation of SIRS, we applied the generally
accepted pediatric consensus criteria [17]. So far, no other
trial has assessed the incidence of SIRS in critically ill
Fig. 1 Incidence of endpoints
in control (blue columns) and
filter group (yellow columns).
Figure presents incidence of
endpoints between control (blue
columns) and filter group
(yellow columns). Upper panel
shows incidence of systemic
inflammatory response
syndrome (SIRS), sepsis, organ
failure (circulation, lung, kidney
and liver) and mortality. Lower
panel displays occurrence of
different organ dysfunctions
(cardiovascular, hematologic,
hepatic, neurologic, renal and
respiratory). SIRS, renal and
hematologic dysfunction were
significantly reduced in the filter
group (asterisk). If the 95 % CI
did not embrace zero, a
statistically significant
difference between both groups
was considered
Table 3 Duration of
mechanical ventilation (MV)
and length of stay (LOS) on
PICU
Endpoints Control group (n = 150) Filter group (n = 155) P value
LOS on PICU (days) 5.86 (4.91–6.82) 4.95 (3.63–6.27) 0.109
Duration of MV (h) 33.0 (12.7–53.3) 18.3 (4.6–31.9) 0.076
Table shows length of stay (LOS) on PICU and duration of mechanical ventilation (MV) for control and
filter groups
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children with cardiac diseases. Our study revealed that
SIRS was a major problem on a cardiac PICU. According
to our data, more than one-third of all patients experienced
at least one episode of SIRS. In-line filtration effectively
reduced the incidence of SIRS and thereby might lower the
morbidity of cardiac intensive care patients. Patients suf-
fering from SIRS have a higher risk to develop sepsis [28],
ARDS, disseminated intravascular coagulation, acute renal
failure or even die of SIRS [27]. Moreover, according to
our data [20] and also demonstrated by others, SIRS is
associated with both prolonged stay on PICU and extended
MV [31]. In-line filtration represents the first preventive
strategy reducing a systemic inflammation and comor-
bidities on PICU.
The control group suffered from a higher incidence of
hematological dysfunction characterized by thrombocy-
topenia and coagulopathy. As patients with CHD per se and
even more pronounced in cyanotic CHD show an altered
hemostatic physiology with decreased concentrations of
coagulation factors and abnormalities of platelets [14], an
additional infusion of particles obstructing small capillaries
may worsen the preexisting coagulopathy [34, 35]. No
cardiac right-to-left shunt provided, in patients without
particle-retentive in-line filters, the lung capillaries are the
first endogenous filters for intravenously infused particles
[15, 34, 35]. Particles trapped in lung capillaries, form
occlusive microthrombi and induce an activation of com-
plement, platelets and neutrophils [34, 35]. But, blockage
of vessels is not only restricted to the lung. Even without a
relevant cardiac right-to-left shunt, intravenously injected
particles are distributed from the lung to the systemic cir-
culation and several organs such as blood, liver, kidney and
spleen [12, 29]. Here, they may induce a systemic hyper-
coagulability. These systemic effects on different organ
systems might be even more pronounced in patients with
CHD and right-to-left shunts. As the coagulation and in-
flammatory system are closely linked in multiple ways
[25], this cross-link may contribute to a further aggravation
of both hypercoagulation and SIRS. In our study, this
deleterious linkage becomes clinically apparent in the
control group: Patients without in-line filters suffered from
a higher incidence of SIRS and coagulopathy. Especially in
patients after cardiac surgery with CPB, the physiological
hemostasis of the coagulation system is altered for several
days postoperatively [8, 21] as the contact of blood to the
artificial surfaces of the CPB circuit causes an activation
and consumption of platelets and coagulation factors [8]. A
further infusion of particles on ICU as in the control group
may additionally trigger the coagulation cascade and con-
tribute to the coagulopathy. This systemic hypercoagula-
bility also plays a relevant role in the pathogenesis of
microvascular impairment and organ failure at multiple
sites [25].
As demonstrated in our study, cardiac patients who are
not protected by particle-retentive in-line filters had a
higher incidence of renal dysfunction. An infusion of par-
ticles may disturb the renal vascular integrity and enhance
the susceptibility to organ dysfunction. Especially patients
with cyanotic CHD have an increased risk of developing
renal impairment [2]. Many studies have shown protein-
uria, reduced glomerular filtration rate, and proliferation of
renal tubular and glomerular cells in patients with CHD
[2]. Contributing factors such as CPB may further augment
the effects of particle infusion. Renal injury following CPB
is frequent, and its pathogenesis is multifactorial [1]. Is-
chemia–reperfusion injury, oxidative stress, microem-
bolization and the inflammatory response have been
accused for the development of renal injury [1, 18]. The
increased incidence of renal impairment may also con-
tribute to a prolonged stay on PICU and extended MV as
shown in children after cardiac surgery [26].
In the control group lacking in-line filters, particles
obstructing lung capillaries trigger the complement system
and activate platelets and neutrophils [15, 34, 35]. This
inflammatory process may lead to an intensified and pro-
longed MV as shown for the control group in the main
study population [20]. In patients after cardiac surgery with
CPB, the effect of particle infusion may be even more
pronounced and the pulmonary inflammation exaggerated.
During CPB, the lungs are excluded from the circulation
and remain ischemic and hypoxic for a long period [4]. The
following reperfusion induces an inflammatory response
with formation of free oxygen radicals and endothelial
injury [4]. Beyond this local pulmonary inflammation,
several inflammatory mediators released during CPB sti-
mulate the proliferation of neutrophils and their migration
to lung capillaries [4]. Here they additionally induce an
endothelial cell swelling and an inflammation in the in-
terstitial tissue and alveoli [4]. A further particle infusion
may aggravate this postperfusion lung syndrome.
The differences in the clinical findings between the
control and the filter group might be attributed to a further
deterioration of microvascular perfusion by particulate in-
fusion in the control group. Microcirculatory disturbance
occurs frequently in critically ill patients and leads to organ
malfunction [13]. With already preexisting microvascular
impairment, an additional infusion of particles causes a
further loss of microvascular density as demonstrated in
preclinical animal studies [24, 29]. In the same ex-
perimental settings, use of particle-retentive in-line filters
was able to completely prevent these effects [29]. There-
fore, in-line filtration may account for the maintenance of
microvascular integrity and thereby preserve the multiple
organ functions within the interventional group. One could
assume that any critically ill patient regardless the under-
lying disease would benefit from the potential protective
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properties of in-line filtration on microcirculation. Espe-
cially during cardiac surgery, both the inflammatory re-
sponse to CPB and the hemodynamic and metabolic
changes alter the microcirculatory perfusion and decrease
capillary density [11, 13]: a condition that persists at least
for the first 24 postoperative hours on ICU [11]. In this
state, additional microcirculatory impairment may exceed
the level of organ retrieval and organ dysfunction becomes
clinically apparent. An early recovery of microcirculation
is therefore associated with a faster restoration of organ
function [33] in the interventional group.
Limitations
Size and power of this investigation were computed for
neither a reduction of a single complication nor a subgroup
analysis. Since many complications were reduced in the in-
line filter group yet without statistical significance, future
studies comprising an appropriate sample size are required
to confirm this trend. Particularly in patients with right-to-
left shunts, a higher amount of infused particles enters
directly the systemic circulation bypassing the lung as
endogenous filter. Therefore, one would expect a higher
incidence of malfunction of those organs supplied by the
systemic circulation. Unfortunately, in our study, the
number of patients with cyanotic CHD was too small to
allow any reliable statistical evaluation. Further prospec-
tive studies will be needed to corroborate this hypothesis.
Placement of in-line filters into infusion lines was not
blinded. This may have affected handling with drugs and
infusion solutions. A study design with unmasked, visible
in-line filters was obligate for a safe drug application and
monitoring of upcoming clogging of the filter membrane.
Conclusion
Particulate contaminations of infusion solutions pose an
additional risk to cardiac intensive care patients. Preven-
tion of particulate infusion by in-line filtration reduces the
incidence of SIRS and preserves renal and hematologic
function. Further prospective randomized trials are needed
to confirm our results.
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